Prabhudas Lilladher has maintained a positive outlook on Eris Lifesciences, setting a price target of ₹1,500. The firm remains optimistic about growth from insulin and diabetes products, even as the company manages temporary operational challenges at its Swiss Parenterals facility.
Brokerage firm Prabhudas Lilladher has reaffirmed its positive stance on Eris Lifesciences, projecting a share price target of ₹1,500. This outlook is based on the company's expansion into specialized areas like insulin analogues, Semaglutide, and biologics. Analysts noted that the firm's growth trajectory remains supported by the commercial ramp-up of its new manufacturing facility in Bhopal, which is expected to play a major role in long-term earnings.
While the long-term potential for these products is a key driver for the positive outlook, the company is currently navigating immediate operational hurdles. A significant part of the discussion surrounds the Swiss Parenterals unit, where remediation efforts are underway. Management has indicated that these operational adjustments may lead to near-term pressure on profit margins, estimated at approximately 200 basis points. Because of these constraints, the company is currently seeing a period of more moderate growth, which the brokerage expects to persist before momentum improves.
In terms of financial performance, Eris Lifesciences reported an EBITDA (operating profit) of ₹3.1 billion for the second quarter, representing a 7% increase compared to the same period last year. This result was generally in line with analyst expectations. Looking ahead, the company is targeting a recovery in profit margins starting in the second half of the current fiscal year. This recovery is expected to be driven by the scaling of production at the Bhopal site and expected improvements in gross margins from the third quarter.
Eris Lifesciences operates primarily in the branded formulations space, with a strong focus on chronic therapy areas such as cardiology and diabetes. This segment is typically stable, though it requires constant product innovation to maintain market share. Investors may watch for the pace of the Swiss Parenterals remediation, as this will be a key factor in how quickly the company can return to its normalized margin levels. The progress of the insulin and diabetes franchise will also remain a monitorable to determine if the company can meet its growth targets for the upcoming financial years.